96978 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Cytokines; Lymphokines; Interferons; Interferons [IFN] IFN-alpha
Fusion Protein Composition(S) Comprising Masked Type I Interferons (IFNa and IFNß) For Use in the Treatment of Cancer and Methods Thereof
#2ONCOSELECTIVE THERAPY
#3DUAL CYTOKINE FUSION PROTEINS COMPRISING MULTI-SUBUNIT CYTOKINES
#4CD8 BINDING AGENTS
#5VEGETATION MANAGEMENT SYSTEM AND VEGETATION MANAGEMENT METHOD
#6CLEC9A BINDING AGENTS
#7IMMUNE-CELL TARGETED BISPECIFIC CHIMERIC PROTEINS AND USES THEREOF
#8Mixture Of Interferon Alpha 2B With Modified Sequences Thereof
#9Mixture Of Interferon Alpha 2B With Other Modified Sequences Thereof
#10MODULATION OF DENDRITIC CELL LINEAGES
#11CD8 BINDING AGENTS
#12METHODS OF PRODUCING RECOMBINANT ADENOVIRUS VECTORS
#13THERAPEUTIC CYTOKINES AND METHODS
#14TREFOIL FACTOR 2/INTERFERON alpha2 FUSION PROTEIN AND APPLICATION THEREOF IN PREVENTION AND TREATMENT OF VIRAL INFECTIOUS DISEASES
#15PD-1 AND PD-L1 BINDING AGENTS
#16ANTI-CD38 FUSION PROTEIN FORMULATION
#17CLEC9A-BASED CHIMERIC PROTEIN COMPLEXES
#18Fusion Protein Composition(s) Comprising Masked Type I Interferons (IFNa and IFNb) For Use in the Treatment of Cancer and Methods Thereof
#19INTERFERON-ASSOCIATED ANTIGEN BINDING PROTEINS FOR USE FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION
#20Vector
#21METHODS OF TREATING MULTIPLE SCLEROSIS USING AUTOLOGOUS T CELLS
#22DOSAGE REGIMEN FOR PEGYLATED INTERFERON
#23THERAPEUTIC NUCLEIC ACID MOLECULE, MIXTURE, AND DRUG, AND USE THEREOF IN TREATING SOLID TUMOR
#24ACTIVATABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS
#25NOVEL INTERFERON VARIANTS AND BIFUNCTIONAL FUSION MOLECULES THEREOF
#26BISPECIFIC RECOMBINANT PROTEIN AND USE THEREOF
#27MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
#28FUSION PROTEIN OF INTERFERON (IFN) AND ANTI-PD-L1 ANTIBODY AND USE THEREOF
#29ACTIVATABLE CYTOKINE CONSTRUCTS AND COMBINATION METHODS
#30MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE
#31A GPC3-targeting antibody-interferon a fusion protein and a use thereof
#32DUAL CYTOKINE FUSION PROTEINS COMPRISING MULTI-SUBUNIT CYTOKINES
#33MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS
#34IMMUNOMODULATORY MOLECULES AND USES THEREOF
#35TARGETED INTERFERON ALPHA FUSION PROTEINS AND METHODS OF USE
#36SIRP1a TARGETED CHIMERIC PROTEINS AND USES THEREOF
#37MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
#38INTERFERON ALPHA-2 VARIANTS
#39METHODS FOR INDUCING AN IMMUNE RESPONSE BY ADMINISTERING ACTIVATED MESENCHYMAL STEM CELLS
#40ANTIBODIES TARGETING BAFF-R AND USE THEREOF
#41IMMUNOGLOBULIN FUSION PROTEINS AND USES THEREOF
#42MULTISPECIFIC PROTEINS COMPRISING AN NKP46-BINDING SITE, A CANCER ANTGIENGE BINDING SITE FUSED TO A CYTOKINE FOR NK CELL ENGAGING
#43BISPECIFIC BINDING AGENT-LIGAND FUSIONS FOR THE DEGRADATION OF TARGET PROTEINS
#44IMMUNOGLOBULIN FUSION PROTEINS
#45IMMUNOGLOBULIN FUSION PROTEINS AND USES THEREOF
#46MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS
#47MASKED ACTIVATABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHOD
#48COMPOSITIONS AND METHODS RELATING TO THE TREATMENT OF DISEASES
#49INTERFERON RECEPTOR AGONISTS AND USES THEREOF
#50GENETIC ENGINEERING OF MACROPHAGES FOR IMMUNOTHERAPY
#51INTERFERON RECEPTOR AGONISTS AND USES THEREOF
#52IMMUNE ACTIVATING Fc DOMAIN BINDING MOLECULES
#53THERAPEUTIC TARGETING OF NON-CELLULAR STRUCTURES
#54COMPOSITIONS AND METHODS RELATING TO THE TREATMENT OF DISEASES
#55Mesothelioma Gene Therapy
#56BISPECIFIC RECOMBINANT PROTEIN AND USE THEREOF
#57METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN
#58CDKN2A companion diagnostic for bladder cancer interferon therapy
#59PD-1 AND PD-L1 BINDING AGENTS
#60ENHANCED-AFFINITY ANTI-ECM NANOBODY-CYTOKINE FUSIONS AND THEIR APPLICATIONS
#61DUAL CYTOKINE FUSION PROTEINS COMPRISING MULTI-SUBUNIT CYTOKINES
#62COLLAGEN-TARGETED FUSION PROTEINS AND ANTIBODIES
#63METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN
#64METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN
#65METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN
#66METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN
#67METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN
#68METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN
#69VIRAL VECTORS EXPRESSING THERAPEUTIC PROTEINS SPECIFICALLY IN MYELOID CELLS AND MICROGLIA
#70HYBRID INTERFERONS FOR TREATING VIRAL INFECTIONS
#71ACTIVATABLE CYTOKINE CONSTRUCTS AND COMBINATION METHODS
#72PROPROTEINS AND METHODS OF USE THEREOF
#73INTERFERON ALPHA 2 VARIANTS AND USES THEREOF
#74A PROTEIN COMPLEX COMPRISING AN IMMUNOCYTOKINE
#75CD8 BINDING AGENTS
#76DOSAGE REGIMEN FOR PEGYLATED INTERFERON
#77MODIFIED INTERFERON-ALPHA-2 HAVING REDUCED IMMUNOGENICITY
#78THERAPEUTIC INTERFERON ALPHA 1 PROTEINS
#79FUSOKINES INVOLVING CYTOKINES WITH STRONGLY REDUCED RECEPTOR BINDING AFFINITIES
#80ACTIVATABLE MONOMERIC CYTOKINE-SINGLE CHAIN (SC) FC FUSION PROTEINS AND USES THEREOF
#81PROPROTEINS AND METHODS OF USE THEREOF
#82IMMUNOGLOBULIN CHIMERIC MONOMER-DIMER HYBRIDS
#83PD-L1 TARGETED CHIMERIC PROTEINS AND USES THEREOF
#84Activatable cytokine constructs and related compositions and methods
#85CONJUGATED CHIMERIC PROTEINS
#86Production and Purification Method for Polypeptide
#87CLEC9A BINDING AGENTS
#88FIBROBLAST ACTIVATION PROTEIN BINDING AGENTS AND USE THEREOF
#89Masked activatable interferon constructs
#90Protease deficient filamentous fungal cells and methods of use thereof
#91TARGETED CHIMERIC PROTEINS AND USES THEREOF
#92IMMUNE-CELL TARGETED BISPECIFIC CHIMERIC PROTEINS AND USES THEREOF
#93INTERFERON ALPHA 2B VARIANTS
#94COMPOSITIONS AND METHODS RELATING TO THE TREATMENT OF DISEASES
#95CD20 BINDING SINGLE DOMAIN ANTIBODIES
#96FMS-LIKE TYROSINE KINASE 3 LIGAND (FLT3L)-BASED CHIMERIC PROTEINS
#97CD8 BINDING AGENTS
#98CHIMERIC PROTEINS AND CHIMERIC PROTEIN COMPLEXES DIRECTED TO FMS-LIKE TYROSINE KINASE 3 (FLT3)
#99CHIMERIC ACTIVATORS: QUANTITATIVELY DESIGNED PROTEIN THERAPEUTICS AND USES THEREOF
#100CLEC9A-BASED CHIMERIC PROTEIN COMPLEXES
#101SIRP1α targeted chimeric proteins and uses thereof
#102MODULATION OF DENDRITIC CELL LINEAGES
#103NEW IMMUNOCYTOKINES FOR THE TREATMENT OF CANCER
#104EXPOSED COLLAGEN-TARGETED FUSION CYTOKINE FOR IMMUNE MODULATION IN INVASIVE CANCERS AND LESIONS OF INFECTIONS
#105IMMUNOGLOBULIN CHIMERIC MONOMER-DIMER HYBRIDS
#1065T4 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF
#107ONCOLYTIC ADENOVIRUS ENCODING A B7 PROTEIN
#108ASPGR ANTIBODIES AND USES THEREOF
#109FUSION PRODUCTS AND BIOCONJUGATES CONTAINING MIXED CHARGE PEPTIDES
#110METHODS AND COMPOSITIONS FOR TREATMENT OF INTERFERON-RESISTANT TUMORS
#111Activatable cytokine constructs and related compositions and methods
#112MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE
#113TUMOR-SPECIFIC IFNA SECRETION BY CAR T-CELLS TO REPROGRAM THE SOLID TUMOR MICROENVIRONMENT
#114Oncolytic virus or antigen presenting cell mediated cancer therapy using type I interferon and CD40-ligand
#115Therapeutic targeting of non-cellular structures
#116TARGETING OF HUMAN INTERFERON ANTAGONISTS
#117Fusion proteins composed of an interleukin-2 mutein and type I interferon
#118Methods for inducing an immune response by administering activated mesenchymal stem cells
#119TARGETED ENGINEERED INTERFERON AND USES THEREOF
#120Methods of administering mesenchymal stem cells activated by cytokines for enhancing immunosuppression
#121Fusion protein and its applicaton in preparing medicine for treating tumor and/or viral infection
#122PEGYLATED PORCINE INTERFERON AND METHODS OF USE THEREOF
#123TARGETED HUMAN-INTERFERON FUSION PROTEINS
#124Fusion protein of interferon (IFN) and anti-PD-L1 antibody and use thereof
#125Protease deficient filamentous fungal cells and methods of use thereof
#126BISPECIFIC SIGNALING AGENTS AND USES THEREOF
#127MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
#128ANTIBODY-INTERFERON FUSION PROTEINS FOR ENHANCING ADOPTIVE T CELL THERAPIES FOR THE TREATMENT OF CANCER
#129IN VIVO PRODUCTION OF PROTEINS
#130Cytokine fusion proteins
#131BI-FUNCTIONAL PROTEINS AND CONSTRUCTION THEREOF
#132PD-1 and PD-L1 binding agents
#133RECOMBINANT HUMAN INTERFERON-LIKE PROTEINS
#134CDKN2a Companion Diagnostic for Bladder Cancer Interferon Therapy
#135XCR1 BINDING AGENTS AND USES THEREOF
#136MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS
#137Method of treating glioblastoma multiforme
#138Expression of metabolic modulators in tumor microenvironment to improve tumor therapy
#139Therapeutic interferon alpha 1 proteins
#140PROPROTEINS AND METHODS OF USE THEREOF
#141Immunocytokines for the treatment of cancer
#142Fusion proteins for treating cancer and related methods
#143ANTI-SERUM ALBUMIN BINDING VARIANTS
#144T CELL RECEPTOR FUSIONS AND CONJUGATES AND METHODS OF USE THEREOF
#145SYSTEMS AND METHODS FOR USING BEHAVIOR DATA OF IMPURITIES AND TARGET PROTEINS TO DESIGN DOWNSTREAM PROCESSES
#146MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
#147CD8 binding agents
#148SYSTEMS AND METHODS FOR MANUFACTURING BIOLOGICALLY-PRODUCED PRODUCTS
#149T CELL RECEPTOR FUSIONS AND CONJUGATES AND METHODS OF USE THEREOF
#150Mesothelioma Gene Therapy
#151Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
#152Genetic engineering of macrophages for immunotherapy
#153Type I interferon signatures and methods of use
#154Methods and compositions for promoting immune cell function
#155INTERFERON PRODRUG FOR THE TREATMENT OF CANCER
#156ASPGR antibodies and uses thereof
#157Interferon alpha 2B variants
#158Targeted chimeric proteins and uses thereof
#159Targeted engineered interferon and uses thereof
#160Immunoglobulin chimeric monomer-dimer hybrids
#161Type I and type III interferon fusion molecules and methods for use thereof
#162IL-10 EGFR antibody fusion protein and uses thereof
#163PANTIDS FOR TREATMENT OF AUTOIMMUNE DISORDERS
#164COMPOSITION FOR INCREASING EXPRESSION LEVEL OF INTERFERON IN ANIMAL CELLS USING PLANT-DERIVED DNA DEMETHYLASE, ANTIVIRAL COMPOSITION, AND METHOD USING SAME
#165Modified polynucleotides for the production of secreted proteins
#166Fusion proteins containing luciferase and a polypeptide of interest
#167METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN
#168Methods and Compositions for Treatment of Interferon-Resistant Tumors
#169Bispecific signaling agents and uses thereof
#170Clec9A binding agents
#171Immune-cell targeted bispecific chimeric proteins and uses thereof
#172METHODS OF TREATING MULTIPLE SCLEROSIS USING AUTOLOGOUS T CELLS
#173Modified polynucleotides for the production of secreted proteins
#174In vivo production of proteins
#175Seeding An Adherent Cell Bioreactor With Non-Adherent Cells Increases Seeding Density Limit And Reduces Required Expansion Time
#176CYSTEINE VARIANTS OF INTERLEUKIN-11 AND METHODS OF USE THEREOF
#177IgG Fc fragment for a drug carrier and method for the preparation thereof
#178MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
#179METHOD FOR DETECTING CROSSLINKED PEPTIDES VIA REPRODUCIBLE FRAGMENTATION IN A MASS SPECTROMETER
#180Protease deficient filamentous fungal cells and methods of use thereof
#181Fusion proteins for treating cancer and related methods
#182Pegylated porcine interferon and methods of use thereof
#183Method for reducing immunogenicity of RNA
#184Combination of lenalidomide and polypeptide construct, and uses thereof
#185Compositions and methods relating to the treatment of diseases
#186Anti-CSPG4 fusions with interferon for the treatment of malignancy
#187CD20 binding single domain antibodies
#188TRANSGENE EXPRESSION IN AVIANS
#189Method of preparing porcine circovirus type 2 capsid protein and pharmaceutical composition comprising same
#190Method of treating diseases with recombinant human interferon-like proteins
#191Oncolytic adenovirus encoding a B7 protein or active fragment
#192CD8 binding agents
#193Methods of producing activated mesenchymal stem cells
#194ASPGR ANTIBODIES AND USES THEREOF
#195Tumor-specific IFNA secretion by car T-cells to reprogram the solid tumor microenvironment
#196Fusokines involving cytokines with strongly reduced receptor binding affinities
#197MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF COSMETIC PROTEINS AND PEPTIDES
#198Biosynthetic proline/alanine random coil polypeptides and their uses
#199Vectors Conditionally Expressing Protein
#200TARGETING OF CYTOKINE ANTAGONISTS
#201Targeting of human interferon antagonists
#202Targeted and mutated human-interferon fusion proteins
#203PROTEIN COMPLEX USING AN IMMUNOGLOBULIN FRAGMENT AND METHOD FOR THE PREPARATION THEREOF
#204FOCUSED INTERFERON IMMUNOTHERAPY FOR TREATMENT OF CANCER
#205Modified Polynucleotides for the production of biologics and proteins associated with human disease
#206Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
#207Compositions and methods relating to the treatment of diseases
#208Exposed collagen-targeted fusion cytokine for immune modulation in invasive cancers and lesions of infections
#209ALBUMIN FUSION PROTEINS
#210EFFICIENT PRODUCTION OF PEPTIDES
#211MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
#212CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
#213Fusokines involving cytokines with strongly reduced receptor binding affinities
#214Oncolytic adenovirus encoding a B7 protein
#215ASPGR antibodies and uses thereof
#216MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
#217Fusion protein comprising , translation interrupter sequence, and interferon amino acid sequences
#218Targeting of human interferon antagonists
#219Oncolytic adenovirus encoding a B7 protein
#220Targeted human-interferon fusion proteins
#221Modified polynucleotides for the production of oncology-related proteins and peptides
#222Method to increase the number of circulating platelets by administering PEGylated cysteine variants of IL-11
#223Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
#224METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES
#225In vivo production of proteins
#226Proteinaceous heterodimer and use thereof
#227CROSSLINKING OF CD22 BY EPRATUZUMAB TRIGGERS BCR SIGNALING AND CASPASE-DEPENDENT APOPTOSIS IN HEMATOPOIETIC CANCER CELLS
#228Dosage regimen for pegylated interferon
#229CHIMERIC ACTIVATORS: QUANTITATIVELY DESIGNED PROTEIN THERAPEUTICS AND USES THEREOF
#230Anti-serum albumin binding variants
#231Protease deficient filamentous fungal cells and methods of use thereof
#232Immunoglobulin chimeric monomer-dimer hybrids
#233Oncolytic adenovirus encoding a therapeutic protein or active fragment
#234Cleavage-activatable interferon-alpha proprotein
#235Fusions of antibodies to CD38 and attenuated interferon alpha
#236Immunoglobulin chimeric monomer-dimer hybrids
#237Combination of lenalidomide and polypeptide construct, and uses thereof
#238Compositions and methods relating to the treatment of diseases
#239Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology
#240Targeted interferons demonstrate potent apoptotic and anti-tumor activities
#241ALBUMIN FUSION PROTEINS
#242Genetic engineering of macrophages for immunotherapy
#243Engineered antibody-interferon mutant fusion molecules
#244Targeted human-interferon fusion proteins
#245Tetrameric cytokines with improved biological activity
#246Oncolytic adenovirus encoding a B7 protein or active fragment
#247Seeding An Adherent Cell Bioreactor With Non-Adherent Cells Increases Seeding Density Limit And Reduces Required Expansion Time
#248Fusion proteins for treating cancer and related methods
#249MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
#250Recombinant human interferon-like proteins
#251Modified polynucleotides for the production of secreted proteins
#252Immunoglobulin fusion proteins and uses thereof
#253IMMUNOGLOBULIN FUSION PROTEINS AND USES THEREOF
#254Method of using a transgenic chicken to produce exogenous proteins in its eggs
#255Multimeric Complexes with Improved in Vivo Stability, Pharmacokinetics and Efficacy
#256Biologically active proteins having increased in vivo and/or in vitro stability
#257Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
#258METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES
#259Targeting of human interferon antagonists
#260Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
#261ALBUMIN FUSION PROTEINS
#262Modified polynucleotides for the production of proteins
#263Methods for the expression of peptides and proteins
#264Biosynthetic proline/alanine random coil polypeptides and their uses
#265Interferon alpha 2B variants
#266Anti-CSPG4 fusions with interferon for the treatment of malignancy
#267CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
#268Anti-serum albumin binding variants
#269Modified polynucleotides for the production of biologics and proteins associated with human disease
#270CONJUGATES FOR THE ADMINISTRATION OF BIOLOGICALLY ACTIVE COMPOUNDS
#271Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
#272Methods And Compositions For Treatment Of Interferon-Resistant Tumors
#273Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
#274In vivo production of proteins
#275Modified polynucleotides for the production of secreted proteins
#276INTERFERON TREATMENT TARGETING MUTANT P53 EXPRESSING CELLS
#277Expression of human interferon in transgenic chloroplasts
#278Albumin fusion proteins
#279Combination of lenalidomide and polypeptide construct, and uses thereof
#280ASGPR antibodies and uses thereof
#281COMPOSITIONS AND METHODS FOR IMPROVING PRODUCTION OF RECOMBINANT POLYPEPTIDES
#282Albumin fusion proteins
#283Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
#284Soluble notch receptor proproteins and methods of use thereof
#285Interferon-alpha fusion protein in which cytoplasmic transduction peptide and polyethylene glycol are bonded to one another
#286Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
#287Modified polynucleotides for the production of cosmetic proteins and peptides
#288Methods of treating tumors with engineered antibody-interferon mutant fusion molecules
#289Immunoglobulin chimeric monomer-dimer hybrids
#290MICRO-ORGANS PROVIDING SUSTAINED DELIVERY OF A THERAPEUTIC POLYPEPTIDE AND METHODS OF USE THEREOF
#291Codon optimized sequence for an antiviral protein
#292T CELL RECEPTOR FUSIONS AND CONJUGATES AND METHODS OF USE THEREOF
#293IgG Fc fragment for a drug carrier and method for the preparation thereof
#294IgG Fc fragment for a drug carrier and method for the preparation thereof
#295Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
#296Efficient production of peptides
#297Protease deficient filamentous fungal cells and methods of use thereof
#298BIOLOGICALLY ACTIVE PROTEINS HAVING INCREASED IN VIVO AND/OR IN VITRO STABILITY
#299Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof
#300Targeted human-interferon fusion proteins